Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Hong

Showing results (301-310 of 442) with videos related to

Pageof 45
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2021
Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung CarcinomaD Ross Camidge, Daniel Morgensztern, Rebecca S Heist, et al.
Oncoscience|January 15, 2015
Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experienceFernando F Corrales-Medina, Cynthia Herzog, Kenneth Hess, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2019
Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic CancerSeyed Pairawan, Kenneth R Hess, Filip Janku, et al.
Nature Biomedical Engineering|January 5, 2021
A mathematical model for the quantification of a patient's sensitivity to checkpoint inhibitors and long-term tumour burdenJoseph D Butner, Zhihui Wang, Dalia Elganainy, et al.
NPJ Precision Oncology|April 10, 2026
Outcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 studyJacopo Venturini, Mehmet A Baysal, Abhijit Chakraborty, et al.
Nature Medicine|January 4, 2024
Sotorasib with panitumumab in chemotherapy-refractory KRAS<sup>G12C</sup>-mutated colorectal cancer: a phase 1b trialYasutoshi Kuboki, Marwan Fakih, John Strickler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2017
Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care ActKenneth L Kehl, Cheryl P Fullmer, Siqing Fu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2012
A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomasDavid S Hong, Razelle Kurzrock, Jeffrey G Supko, et al.
JTO Clinical and Research Reports|January 10, 2022
A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLCD Ross Camidge, Fabrice Barlesi, Jonathan W Goldman, et al.
Molecular Cancer Therapeutics|October 5, 2013
Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutationsPrasanth Ganesan, Filip Janku, Aung Naing, et al.
Pageof 45

Showing results (301-310 of 442) with videos related to

Sort By:
Pageof 45
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2021
Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung CarcinomaD Ross Camidge, Daniel Morgensztern, Rebecca S Heist, et al.
Oncoscience|January 15, 2015
Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experienceFernando F Corrales-Medina, Cynthia Herzog, Kenneth Hess, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2019
Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic CancerSeyed Pairawan, Kenneth R Hess, Filip Janku, et al.
Nature Biomedical Engineering|January 5, 2021
A mathematical model for the quantification of a patient's sensitivity to checkpoint inhibitors and long-term tumour burdenJoseph D Butner, Zhihui Wang, Dalia Elganainy, et al.
NPJ Precision Oncology|April 10, 2026
Outcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 studyJacopo Venturini, Mehmet A Baysal, Abhijit Chakraborty, et al.
Nature Medicine|January 4, 2024
Sotorasib with panitumumab in chemotherapy-refractory KRAS<sup>G12C</sup>-mutated colorectal cancer: a phase 1b trialYasutoshi Kuboki, Marwan Fakih, John Strickler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2017
Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care ActKenneth L Kehl, Cheryl P Fullmer, Siqing Fu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2012
A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomasDavid S Hong, Razelle Kurzrock, Jeffrey G Supko, et al.
JTO Clinical and Research Reports|January 10, 2022
A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLCD Ross Camidge, Fabrice Barlesi, Jonathan W Goldman, et al.
Molecular Cancer Therapeutics|October 5, 2013
Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutationsPrasanth Ganesan, Filip Janku, Aung Naing, et al.
Pageof 45